Number of the records: 1
HPMA-based doxorubicin conjugate containing human intravenous immunoglobulin shows anti-cancer effect and protection of immunity
- 1.
SYSNO ASEP 0025007 Document Type C - Proceedings Paper (int. conf.) R&D Document Type Conference Paper Title HPMA-based doxorubicin conjugate containing human intravenous immunoglobulin shows anti-cancer effect and protection of immunity Title Konjugáty na bázi HPMA s doxorubicinem a lidským intravenosním imunoglobulinem mají protinádorový efekt a chrání imunitu Author(s) Šírová, Milada (MBU-M) RID, ORCID
Strohalm, Jiří (UMCH-V)
Mrkvan, Tomáš (MBU-M)
Šubr, Vladimír (UMCH-V) RID, ORCID
Ulbrich, Karel (UMCH-V) RID
Říhová, Blanka (MBU-M) RIDSource Title Keystone symposia. - New Mexico, 2005 Pages s. 48-48 Number of pages 1 s. Action Keystone symposia Event date 17.02.2005-22.02.2005 VEvent location Santa Fe Country US - United States Event type WRD Language eng - English Country US - United States Keywords hpma ; doxorubicin Subject RIV EE - Microbiology, Virology R&D Projects GA305/02/1425 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z5020903 - MBU-M Annotation HPMA-based conjugate containing doxorubicin and human intravenous immunoglobulin was studied in mouse model of EL-4 lymphoma. The conjugate revealed a profound curative capacity. Resistance to the same tumour developed in the treated animals pointing to a protective effect of the treatment toward the immune anti-cancer responses Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2006
Number of the records: 1